Known targets — ChEMBL curated mechanism
DHFRGARTPTGFRPTGIRPTGS1PTGS2TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8envmurAthyA
The experimentally established mechanism targets of Tromethamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.32 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.32 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tromethamine SCHEMBL23041034 | 1.00 | ALDH1A1 (0.36) | ALDH1A1KDM4EKMT2ALMNAHTT | |
| Tromethamine SCHEMBL6320590 | 0.98 | ALDH1A1 (0.35) | ALDH1A1KDM4EKMT2ALMNAHTT | |
| SCHEMBL3717128 | 0.89 | ALDH1A1 (0.43) | ALDH1A1KDM4EKMT2ALMNAHTT | |
| SCHEMBL2229127 | 0.87 | ALDH1A1 (0.45) | ALDH1A1KDM4EKMT2ALMNAHTT | |
| SCHEMBL9790 | 0.87 | ALDH1A1 (0.45) | ALDH1A1KDM4EKMT2ALMNAHTT | |
| SCHEMBL2417 | 0.87 | ALDH1A1 (0.45) | ALDH1A1KDM4EKMT2ALMNAHTT | |
| SCHEMBL3122895 | 0.85 | — | — | |
| SCHEMBL21752841 | 0.85 | ALDH1A1 (0.43) | ALDH1A1KDM4EKMT2ALMNAHTT | |
| SCHEMBL21752846 | 0.85 | ALDH1A1 (0.43) | ALDH1A1KDM4EKMT2ALMNAHTT | |
| SCHEMBL21752879 | 0.85 | ALDH1A1 (0.43) | ALDH1A1KDM4EKMT2ALMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024140721-A1 | REAGENT FOR DETECTING GLYCATED HEMOGLOBIN, DETECTION METHOD, AND USE | 深圳迈瑞生物医疗电子股份有限公司 | 2024-07-04 | — | — | WO | disclosed |
| WO-2024055378-A1 | PROTEIN-ANTIGEN COMBINATION FOR DETECTING AUTOANTIBODIES IN ALZHEIMER'S DISEASE, AND USE THEREOF | 北京湃德智健科技有限公司 | 2024-03-21 | — | — | WO | disclosed |
| WO-2023227028-A1 | NOVEL CAS EFFECTOR PROTEIN, GENE EDITING SYSTEM, AND USE | 广州瑞风生物科技有限公司 | 2023-11-30 | — | — | WO | disclosed |
| US-20230102656-A1 | COVALENT INHIBITORS OF CORONAVIRUS PAPAIN-LIKE PROTEASE | U. S. DEPARTMENT OF ENERGY | 2023-03-30 | — | — | US | disclosed |
| WO-2023030407-A1 | POLYPEPTIDE TARGETING CHARCOT-LEYDEN CRYSTAL PROTEIN AND USE THEREOF | 首都医科大学附属北京同仁医院 | 2023-03-09 | — | — | WO | disclosed |
| WO-2023028286-A1 | COVALENT INHIBITORS OF CORONAVIRUS PAPAIN-LIKE PROTEASE | UT-BATTELLE, LLC (US) | 2023-03-02 | — | — | WO | disclosed |
| WO-2021210189-A1 | PATHOGEN QUANTUM CRYSTAL SOLID-PHASE SUBSTRATE AND QUANTUM CRYSTAL SOLID-PHASE FLUORESCENCE COUNTING METHOD | 有限会社マイテック | 2021-10-21 | — | — | WO | disclosed |
| WO-2021033530-A1 | METHOD FOR PRODUCING RADIOACTIVE METAL COMPLEX | 日本メジフィジックス株式会社 | 2021-02-25 | — | — | WO | disclosed |
| WO-2020257866-A1 | ISOTACHOPHORETIC NUCLEIC ACID TRANSFORMATION OF CELLS | UNIVERSITY OF TASMANIA (AU) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020262413-A1 | METHOD FOR ANALYZING MICROBIAL FLORA | 国立研究開発法人産業技術総合研究所 | 2020-12-30 | — | — | WO | disclosed |
| EP-0731727-A1 | POLYHYDROXYBUTYRATE AND POLYPHOSPHATE MEMBRANES WITH CHANNELS | MICHIGAN STATE UNIVERSITY (US) | 1996-09-18 | — | — | EP | disclosed |
| WO-1996014077-A1 | PERIPHERAL NERVOUS SYSTEM SPECIFIC SODIUM CHANNELS, DNA ENCODING THEREFOR, CRYSTALLIZATION, X-RAY DIFFRACTION, COMPUTER MOLECULAR MODELING, RATIONAL DRUG DESIGN, DRUG SCREENING, AND METHODS OF MAKING AND USING THEREOF | TROPHIX PHARMACEUTICALS, INC. (US) | 1996-05-17 | — | — | WO | disclosed |
| WO-1996010454-A1 | POLYHYDROXYBUTYRATE AND POLYPHOSPHATE MEMBRANES WITH CHANNELS | MICHIGAN STATE UNIVERSITY (US) | 1996-04-11 | — | — | WO | disclosed |
| EP-0683774-A1 | HYPOLIPIDAEMIC COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-11-29 | — | — | EP | disclosed |
| EP-0626952-A1 | HYPOLIPIDAEMIC BENZOTHIAZEPINE COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-12-07 | — | — | EP | disclosed |
| WO-1994018184-A1 | HYPOLIPIDAEMIC COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-08-18 | — | — | WO | disclosed |
| US-5328840-A | Binding with peptides a biocompatible molecule | THE RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORK (US) | 1994-07-12 | — | — | US | disclosed |
| EP-0558645-A1 | ERYTHROCYTES AND THROMBO-ERYTHROCYTES AS TARGET SPECIFIC AGENTS | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1993-09-08 | — | — | EP | disclosed |
| WO-1993016055-A1 | HYPOLIPIDAEMIC BENZOTHIAZEPINE COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-08-19 | — | — | WO | disclosed |
| WO-1992008804-A1 | ERYTHROCYTES AND THROMBO-ERYTHROCYTES AS TARGET SPECIFIC AGENTS | THE RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORK (US) | 1992-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230102656-A1 | COVALENT INHIBITORS OF CORONAVIRUS PAPAIN-LIKE PROTEASE | CPN1, CTRL, CTRC | ALDH1A1 1621/4885KDM4E 2821/4885KMT2A 1749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.